| Date | Title | Description |
| 25.06.2025 | Neuron23: Pioneering Precision Medicine with a $96.5 Million Boost | In the ever-evolving landscape of biotechnology, Neuron23 stands as a beacon of hope. This San Francisco-based company has just secured $96.5 million in Series D funding, a significant leap forward in its mission to develop precision medici... |
| 25.06.2025 | Neuron23 Raises $96.5M in Series D Financing | Neuron23, a San Francisco, CA-based clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, raised $96.5M in Series D funding.
The round wa sled by heal... |
| 24.06.2025 | Neuron23: $96.5 Million Series D Raised For Advancing Neurological And Immunological Medicines | Neuron23 – a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases – announced the closing of a $96.5 million Series D funding round led by a healthcar... |
| 03.04.2024 | Addex spin-off launched with USD63 million investment |
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Today the company announced that it will contribute a portfolio of... |